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Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2)
have complex actions in angiogenesis and vascular
remodeling due to their effects on Tie2 receptor sig-
naling. Ang2 blocks Ang1-mediated activation of Tie2
in endothelial cells under certain conditions but is a
Tie2 receptor agonist in others. We examined the
effects of selective inhibitors of Ang1 (mL4-3) or Ang2
(L1-7[N]), alone or in combination, on the vasculature
of human Colo205 tumors in mice. The Ang2 inhibi-
tor decreased the overall abundance of tumor blood
vessels by reducing tumor growth and keeping vascu-
lar density constant. After inhibition of Ang2, tumor
vessels had many features of normal blood vessels
(normalization), as evidenced by junctional accumu-
lation of vascular endothelial-cadherin, junctional
adhesion molecule-A, and platelet/endothelial cell
adhesion molecule-1 in endothelial cells , increased
pericyte coverage, reduced endothelial sprouting,
and remodeling into smaller , more uniform ves-
sels. The Ang1 inhibitor by itself had little notice-
able effect on the tumor vasculature. However ,
when administered with the Ang2 inhibitor , the
Ang1 inhibitor prevented tumor vessel normaliza-
tion, but not the reduction in tumor vascularity
produced by the Ang2 inhibitor. These findings are
consistent with a model whereby inhibition of Ang2
leads to normalization of tumor blood vessels by
permitting the unopposed action of Ang1, but de-
creases tumor vascularity primarily by blocking
Ang2 actions. (Am J Pathol 2009, 175:2159–2170; DOI:
10.2353/ajpath.2009.090391)
Solid tumors require angiogenesis—the formation of
new blood vessels from existing vessels—for survival,
growth, and metastasis.1 Tumor vessels are structur-
ally and functionally abnormal.1,2 They exist in a con-
stantly dynamic state of sprout formation, proliferation,
remodeling, or regression. Structurally, tumor vessels
tend to be leaky and tortuous, lacking the hierarchical
arrangement of arterioles, capillaries, and venules.2
Pericytes that attach to and help stabilize normal ves-
sels are loosely associated with the endothelium of
tumor vessels.1,2 These vascular abnormalities result in
impaired and heterogeneous blood flow. In tumors,
angiogenesis inhibitors not only cause vessel regres-
sion or retardation of vessel growth, but they can also
induce vascular normalization.1–3
The complicated regulation of angiogenesis and
vascular maturation involves multiple signaling cas-
cades driven by endothelial-cell specific growth fac-
tors and their receptors. One of these, vascular endo-
thelial growth factor (VEGF) has been extensively
studied,4 but angiopoietins and other growth factors
are also involved.5,6 The angiopoietin ligands (Ang1
and Ang2) and their receptor (Tie2) have essential
roles in vascular development.7,8 Ang1 is produced by
vascular mural cells, pericytes, and certain other cells,
whereas Ang2 and Tie2 are expressed primarily by
endothelial cells.
Angiogenesis and vascular remodeling involve a com-
plex coordination of Ang1 and Ang2 signaling through
Tie2.5 The traditional view of Ang1 and Ang2 signaling is
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that the growth factors have opposing effects on Tie2
receptor activation: Ang1 binds to Tie2 to promote vas-
cular maturation and integrity, whereas Ang2 acts as a
naturally occurring antagonist of Ang1.7–11 Although a
number of studies indicate an antagonistic role of Ang2,
recent studies have shown that Ang2 can have an ago-
nistic role depending on the experimental environ-
ment.12–15 If expressed at high concentrations or for long
durations in cultured endothelial cells, Ang2—like Ang1—
can induce Tie2 receptor phosphorylation.13,16 Ang2 can
also promote chemotaxis, tube formation, migration, and
sprouting of endothelial cells in the absence of Ang1,14
which support the view that Ang2 actions are context-
dependent.
Normalization of tumor vascular morphology and
function has been demonstrated with numerous angio-
genesis inhibitors.1,17,18 Ang1 and Ang2 regulate vas-
cular maturation and integrity during development;
however, their effects on normalization of tumor ves-
sels are not known. Tumors grown in mice lacking
Ang2 have a more mature vascular phenotype, but it is
not known whether Ang1 plays a role.19 The effects of
individual angiopoietins on the tumor vasculature have
not been studied extensively in loss-of-function exper-
iments, due largely to the limited availability of selec-
tive angiopoietin inhibitors. Some clues to the effects of
Ang1 and Ang2 on tumor vessels have been garnered
through overexpression of the ligands in tumor cell
xenografts.20–26 These studies, however, have yielded
conflicting data,20–26 the ligands were administered at
nonphysiological levels, and the results were restricted
to prevention studies. Studies blocking the Tie2 recep-
tor have shown reduced tumor angiogenesis,27–30 but
the specific roles of each ligand cannot be differenti-
ated. Pharmacological angiopoietin inhibitors using
antisense, aptamer, and peptide-Fc fusion protein
(peptibody) technologies are currently being devel-
oped, but published studies have been restricted to
inhibition of Ang1 or Ang2 alone.31–33 Studies using
aptamers or peptibodies that potently neutralize Ang2
activity showed that Ang2 antagonism resulted in inhi-
bition of angiogenesis and tumor growth.31,32 Inhibition
of Ang1 in a cell line stably transfected with antisense
RNA resulted in reduced tumor growth and angio-
genesis.33
To gain a better understanding of the effects of Ang1
and Ang2 on blood vessels in tumors, we used selective
inhibitors (peptibodies) of Ang1 and Ang2, alone or in
combination, in Colo205 tumors. These studies focused
on Colo205 tumors, as this model is sensitive to angio-
poietin inhibitors.31 We found that inhibition of Ang1 alone
had little effect on the tumor vasculature, whereas inhibi-
tion of Ang2 resulted in fewer tumor vessels and normal-
ization of the surviving tumor vessels. When the Ang2
inhibitor was administered with the Ang1 inhibitor, tumor
vessel normalization did not occur, but the Ang2 inhibitor-
mediated reduction in vascularity was unaffected. These
findings suggest that inhibition of Ang2 leads to unop-
posed Ang1 activity and results in normalization of tumor
vessels. In contrast, the Ang2 inhibitor-mediated reduc-
tion in tumor vascularity was Ang1-independent.
Materials and Methods
Animals and Treatment
The Colo205 colorectal tumor model was used as previ-
ously described.31 Colo205 tumors were chosen be-
cause they express both Ang1 and Ang2 and are sensi-
tive to Ang2 inhibitors.31 Human Colo205 tumors grown in
nude mice express human Ang1 (95 copies mRNA),
mouse Ang1 (2683 copies mRNA), human Ang2 (11,758
copies mRNA), and mouse Ang2 (28,721 copies mRNA)
(all copy numbers per 100 ng total mRNA measured by
TaqMan real-time PCR using species-specific probe sets
and recombinant mRNA standard curves; D. Yu, A.
Coxon, and J. Oliner, unpublished data). CD1 nude mice
(Charles River, Wilmington, MA) were injected with 0.2 ml
of tumor cell suspension in RPMI medium plus Cultrex
(R&D Systems, Minneapolis, MN) (3:1) containing 2 
106 Colo205 tumor cells (ATCC, Manassas, VA). Colo205
tumors were allowed to grow for 2 to 3 weeks before
treatment. Mice were treated with an Ang1-specific pep-
tibody (mL4-3) having an IC50 value of 33 pM against
murine Ang1 (T. Lee, A. Coxon, and J. Oliner, unpub-
lished data) or an Ang2-specific peptibody (L1-7[N]) dis-
playing an IC50 of 71 pM against murine Ang2.
31 Mice
bearing Colo205 tumors were injected subcutaneously
daily for 7 or 26 days with normal human IgG1 Fc (hFc,
control, 550 g), mL4-3 (500 g), L1-7(N) (50 g), or
these doses of both inhibitors. The control hFc protein
was added to the treatment groups to match the total
amount of protein delivered in the combination group
(550 g). All experimental procedures were approved
and conducted in accordance with institutional guide-
lines established by the Institutional Animal Care and Use
Committees of the University of California, San Francisco
and Amgen, Inc.
Vascular Perfusion and Tissue Preparation
At the end of the treatment period, mice were anesthe-
tized with ketamine (100 mg/kg) and xylazine (12 mg/kg)
i.p. and tissues were preserved by vascular perfusion of
fixative (1% paraformaldehyde in PBS, pH 7.4) for 2
minutes at a pressure of 120 mmHg.3 Tumors were re-
moved, weighed, fixed in 1% paraformaldehyde for 1
hour at 4°C, immersed in 30% sucrose in PBS overnight,
frozen in optimal cutting temperature compound on dry
ice, and stored at 20°C.
Immunohistochemistry
Sections 60 to 80 m in thickness were cut on a cryostat
and dried on Superfrost plus slides (Fisher Scientific,
Pittsburgh, PA) for 5 hours or overnight. Sections were
permeabilized with PBS containing 0.3% Triton X-100
(Lab Chem Inc., Pittsburg, PA) and blocked in 5% normal
serum (Jackson ImmunoResearch, West Grove, PA) in
PBS (PBS containing 0.3% Triton X-100, 0.2% bovine
serum albumin [Sigma, St. Louis, MO, and 0.01% sodium
azide [Sigma]) for 30 minutes to 1 hour. Sections were
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incubated for 12 to 15 hours in primary antibodies diluted
in 5% normal serum in PBS. After rinsing with PBS
containing 0.3% Triton X-100, sections were incubated at
room temperature in fluorophore-conjugate secondary
antibodies (fluorescein isothiocyanate, Cy3, or Cy5,
Jackson ImmunoResearch) diluted in PBS plus 0.3% Tri-
ton X-100 for 3 to 5 hours. Sections were rinsed with PBS
plus 0.3% Triton X-100, fixed in 4% paraformaldehyde
for 5 to 10 minutes, rinsed in PBS, and mounted in
Vectashield (Vector Laboratories, Burlingame, CA).
Endothelial cells were stained with hamster anti-plate-
let/endothelial cell adhesion molecule (PECAM-1,
CD31, Clone 2H8, 1:500, Thermo Scientific, Hudson,
NH), rat anti-vascular endothelial (VE)-cadherin (1:500,
BD Biosciences, Franklin Lakes, NJ), or rat anti-junc-
tional adhesion molecule (JAM-A) (JAM-1, Clone BV12,
1:20, E. Dejana). Pericytes were stained with rat anti-
platelet derived growth factor receptor- (PDGFR-, clone
APB5, 1:2000, eBioscience, San Diego, CA) or Cy3-conju-
gated anti--smooth muscle actin (clone1A4, 1:1000,
Sigma). Viable tumor cells were identified using the nuclear
dye, YO-PRO-1 (1 mol/L solution, Invitrogen/Molecular
Probes, Carlsbad, CA).
Microscopy and Area Density Measurements
Stained sections were examined with a Zeiss Axiophot
fluorescence microscope equipped with single, dual,
and triple fluorescence filters and a low-light, externally
cooled, three-chip charge-coupled device camera (480 
640 pixel RGB-color images, CoolCam; SciMeasure An-
alytical Systems, Atlanta, GA) and with a Zeiss LSM 510
confocal microscope with argon, helium-neon, and UV
lasers (512  512 or 1024  1024 pixel RGB-color im-
ages). Area density of PECAM and PDGFR- immunore-
activities was measured with ImageJ software (http://
rsbweb.nih.gov/ij/) on digital fluorescence microscopic
images using empirically determined threshold values
(30 to 40 for PECAM; 20 to 25 for PDGFR-).3 Area
density was calculated as the proportion of pixels having
a fluorescence intensity value equal to or greater than the
corresponding threshold.
For CD31 area density measurement, nonviable or
necrotic regions were excluded from the analysis by
selecting the region of interest based on YO-PRO-1 stain-
ing. To measure the area density of PDGFR- positive
pericytes associated with tumor vessels, confocal im-
ages of tumor vessels and pericytes were taken with the
40 objective and 2 zoom and the region of interest
was identified as the area 10 m from the edge of the
tumor vessels stained with PECAM.
PECAM area was used as a reflection of the total amount
of PECAM found in the viable regions of the tumors. Images
of the entire tumor stained with YO-PRO-1 were taken with
the Zeiss Axiophot fluorescence microscope (2.5 ob-
jective, 1 Optovar, tissue region 3696  4928 m or
480  640 pixels) and assembled in Photoshop. Nonvi-
able or necrotic regions were identified by absence of
YO-PRO-1 staining and excluded from measurements.
Total area of the viable tumor (mm2) was calculated from
the number of YO-PRO-1 positive pixels above a thresh-
old of 20 to 30. The area of PECAM immunoreactivity
within viable regions was calculated by multiplying the
area density of PECAM staining in viable areas by the
total area of viable tumor.
Morphometric Measurements
Morphometric measurements of blood vessels were
made on images obtained from 60 to 80 m thick
sections. Vessel diameter was determined in sections
stained for PECAM using the CoolCam CCD camera
attached to a digitizing tablet. Measurements were
made on live images of 100 tumor vessels per tumor, 5 to
6 tumors per treatment group. Statistical differences be-
tween treatment groups were analyzed by the Kolmog-
orov-Smirnov test where P  0.05 was considered
significant.
The number of endothelial sprouts were determined in
samples stained for PECAM as previously described.34
Sprouts were identified as tapered PECAM-immunoreac-
tive processes that extend away from the main axis of a
vessel, which end abruptly. The number of sprouts was
counted on 10 vessel segments for each tumor, with 5 to
6 tumors per group. The length of each vessel segment
was determined using the digitizing tablet. Results are
presented as number of sprouts per vessel segment
length (mm).
Scanning Electron Microscopy
Samples examined by scanning electron microscopy
were prepared and imaged as previously described.3,35
Briefly, tissues were fixed by vascular perfusion of 2%
glutaraldehyde in 100 mmol/L phosphate buffer. The
samples were treated with 30% potassium hydroxide at
60°C for 8 minutes to dissolve the extracellular matrix,
stained with 2% tannic acid and 1% OsO4, dehydrated
with ethanol, critical point dried, coated in an osmium
plasma coater (OPC60A; Filgen, Japan), and exam-
ined with a scanning electron microscope (S-5000;
Hitachi, Brisbane, CA).
Quantification of Endothelial Cell Junctions
The linear staining of endothelial cell junctions was quan-
tified by extending an algorithm based on the multiscale
curvelet transform36 adapted for edge detection in mi-
croscopy images.37 The curvelet transformat was first
applied to the images of tumor blood vessels stained for
PECAM. The information for different scales and their
directions and positions was stored into the curvelet co-
efficients. We performed a lossy image reconstruction by
keeping 75% of the coefficients at all levels, except the
finest, which were discarded. The elimination of the finest
scale during image reconstruction eliminated noise and
small impurities from the image. The image reconstruc-
tion process was robust with the results largely un-
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changed when using between 30% and 95% of the
coefficients.
The reconstructed image was then subjected to a
morphological opening (an erosion followed by a dila-
tion), using a disk of specified radius, which can be
adjusted, as the structural element of the opening op-
eration. This eliminated small, isolated round objects in
the image, enhanced the separation between objects,
and minimized the effects of local variations. Following
this morphological opening, a simple thresholding was
applied to identify the objects with the highest intensity
in the image. The threshold was chosen between two
peaks in the histogram of the curvelet magnitude im-
age. This resulted in a threshold of 90% of the maxi-
mum intensity of the image.
After this processing, the boundaries of the objects on
the image were identified. The borders of each object
were approximated by using straight segment connec-
tions between the points on the boundary. The object was
fitted with cubic splines, which were in turn used to
compute the curvature along the border of the PECAM
staining. A size threshold was then applied to eliminate
objects that span the full length of the image or were just
small isolated blobs.
Statistics
Differences between groups were analyzed by analysis
of variance followed by Fisher’s posthoc tests. Values are
expressed as mean SE. Differences with P 0.05 were
considered significant.
Results
Differences in Tumor Vascularity after Inhibition
of Ang1 and/or Ang2
The four treatments had significantly different effects on
tumor growth (Figure 1A). Tumor growth curves were
essentially the same in mice treated with the control
reagent (hFc) and in mice treated with the Ang1 inhibitor
(mL4-3) (Figure 1A). However, the Ang2 inhibitor (L1-
7[N]) significantly slowed tumor growth (Figure 1A), as
previously reported.31 Addition of the Ang1 inhibitor did
not reverse the effects of the Ang2 inhibitor on tumor
growth; instead, the combination of L1-7(N) and mL4-3
resulted in at least as much slowing of tumor growth as
the Ang2 inhibitor alone (Figure 1A). Although the aver-
Figure 1. Differences in tumor growth and vascularity after inhibition of Ang1 and/or Ang2. A: Growth of Colo205 tumors treated for 26 days with one of four
treatment regimens. Growth rates were similar with hFc and mL4-3 (Ang1 inhibitor) but were significantly slower with L1-7(N) (Ang2 inhibitor) or the combination
of inhibitors. *P 0.01 vs. hFc, **P 0.001 vs. hFc. B: Colo205 tumors stained with the nuclear dye, YO-PRO-1, to show the size of the tumors (green). The tumor
treated with the Ang2 inhibitor or the combination of inhibitors was smaller than after the other treatments. C–F. Confocal images showing PECAM
immunoreactivity (red) of blood vessels surrounded by YO-PRO-1 staining (green) of viable tumor cells in Colo205 tumors treated for 26 days. The vascular density
in YO-PRO-1-positive regions of tumors was similar in control tumors (C, hFc), after inhibition of Ang1 (D, mL4-3), or inhibition of Ang2 (E, L1-7[N]), but was
less after inhibition of Ang1 and Ang2 together (F). The area density of PECAM-positive blood vessels in YO-PRO-1–positive regions was not changed by either
inhibitor alone but was significantly less after the combination of inhibitors (G). Overall tumor vascular mass, calculated as the product of the fractional area of
PECAM staining and tumor size, was significantly less than control after inhibition of Ang2 or after inhibition of Ang1 and Ang2 together (H). *P  0.05 compared
with hFc. Scale bar: 3.5 mm (B); 80 m (C–F).
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age tumor volume was smaller in the combination treat-
ment group than in the L1-7(N) treatment group, this
difference did not reach statistical significance.
To obtain an overview of the effects on tumor vessels
by inhibiting Ang1 or Ang2, alone or together, we identi-
fied viable regions of tumor cells with the nuclear marker
YO-PRO-1 and examined tumor vascularity after staining
blood vessels for PECAM immunoreactivity. Histological
sections made at the end of the experiment confirmed the
smaller tumor size after treatment with the Ang2 inhibitor
alone or the combination of inhibitors (Figure 1B). The
fractional area (area density) of PECAM immunoreactivity
in viable regions of tumors treated with mL4-3 or L1-7(N)
for 26 days was similar to that of hFc-treated (control)
tumors (Figure 1, C–E, G). Only when mice were treated
with both inhibitors together was the fractional area of
tumor vessels significantly less (30%) than the control
(Figure 1, F and G).
To take changes in overall tumor size into account,
total vessel area was calculated. When proportional re-
ductions in tumor size and vessel density are similar, the
fractional area of tumor vessels does not reflect changes
in overall abundance of tumor vessels. Such changes are
reflected by calculations of total tumor vascularity (total
tumor vessel area) from the fractional area of tumor ves-
sels and tumor size. Measurements of fractional area of
tumor vessels in viable regions of the tumor scaled to
tumor size (area density of PECAM staining  mm2 of
viable tumor per section) were, in comparison with hFc
controls, 50% less after the Ang2 inhibitor, and 62% less
after the combination of inhibitors (Figure 1H). These
values indicate that tumors treated with the Ang2 inhibitor
or the drug combination had only half as many blood
vessels, or fewer, than control tumors.
Differences in Tumor Vessel Phenotype after
Inhibition of Ang1 and/or Ang2
Blood vessels of hFc-treated Colo205 tumors had multi-
ple abnormalities, including variability in size, tortuosity,
and presence of sprouts (Figure 2A). After treatment with
the Ang1 inhibitor for 26 days, tumor vessels were similar
to those after hFc (Figure 2B). However, after inhibition of
Ang2, tumor vessels were straighter, more uniform in
caliber, and had fewer sprouts (Figure 2C). When the
Ang1 inhibitor was combined with the Ang2 inhibitor,
tumor vessels were less abundant, had a simpler archi-
tecture, and fewer sprouts compared with control (Figure
2D). After 26 days of treatment, tumor vessels had 14%
fewer sprouts after the Ang1 inhibitor and 40% fewer
sprouts after the Ang2 inhibitor. The two inhibitors in
combination did not reduce the number of sprouts as
much as the Ang2 inhibitor alone, but sprouts were still
significantly (23%) less numerous than in the control (Fig-
ure 2E).
Figure 2. Tumor vessel phenotype after inhibition of Ang1 and/or Ang2. Confocal microscopic images of endothelial cells (PECAM; green) in Colo205 tumors after
treatment for 26 days. Blood vessels are tortuous and sprouting in a control tumor (A, hFc) and after inhibition of Ang1 (B, mL4-3), but are more uniform in size
and have less sprouting after inhibition of Ang2 (C, L1-7[N]). Tumor vessels are less numerous after treatment with both inhibitors (D). Endothelial sprouts were
significantly less numerous after inhibition of Ang2 (E). This reduction in sprouts by the Ang2 inhibitor was not blocked by co-administration of the Ang1 inhibitor
(E). Graph of the size distributions of tumor vessels in the four groups shows that the average size of tumor vessels was significantly less after inhibition of Ang2.
Inhibition of Ang1 reduced this effect (F). *P  0.05 compared with hFc. Scale bar: 50 m.
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Measurements of vessel diameter revealed that tumor
vessels were smaller after inhibition of Ang2 than in the
control or after inhibition of Ang1. This difference was
evident in a left-shift of the vessel size distribution (Figure
2F). When the Ang1 and Ang2 inhibitors were given
together, the distribution of vessel size was significantly
greater than with the Ang2 inhibitor alone (Figure 2F).
Differences in Endothelial Cell Junction Proteins
after Inhibition of Ang1 and/or Ang2
To determine whether the uniformity of vessel size and
reduced sprouting after inhibition of Ang2 were manifes-
tations of tumor vessel normalization, we asked whether
the junctions between endothelial cells acquired a more
normal pattern, consistent with improved barrier function.
We found that staining for the adherens junction protein,
VE-cadherin, was diffuse and weak in the vasculature of
control tumors treated with hFc for 26 days (Figure 3A)
with little or no immunoreactivity located at the intercel-
lular junctions. VE-cadherin had the same appearance in
tumors treated with the Ang1 inhibitor (Figure 3B). By
striking comparison, after inhibition of Ang2, VE-cadherin
staining was more conspicuous because of the linear
pattern that was largely associated with endothelial cell
junctions (Figure 3C), as in normal blood vessels.38 When
the Ang1 inhibitor was administered with the Ang2 inhib-
itor, staining for VE-cadherin was diffuse and had little
association with endothelial cell borders (Figure 3D).
Like VE-cadherin, the tight junction protein JAM-A was
diffuse in the endothelium of tumor vessels after hFc
(Figure 3E) and was similarly faint after treatment with the
Ang1 inhibitor for 26 days (Figure 3F). Also like VE-
cadherin, JAM-A immunoreactivity had strong, linearized
staining that localized to endothelial cell borders after
inhibition of Ang2 (Figure 3G). When the Ang1 inhibitor
was combined with the Ang2 inhibitor, JAM-A was
weaker, more diffuse and had less junction-associated
staining than after the Ang2 inhibitor alone (Figure 3H).
Therefore, the normalization of endothelial cell junctions
that is elicited by inhibition of Ang2 is prevented by
co-inhibition with Ang1.
Although not a component of intercellular junctions,
PECAM is concentrated at cell borders in most normal
blood vessels.39 PECAM immunoreactivity was present in
blood vessels of Colo205 tumors treated with hFc for 26
days, but consisted largely of dots that had no obvious
association with endothelial cell borders (Figure 4A).
PECAM had a similar pattern in the tumor vasculature
after treatment with the Ang1 inhibitor (Figure 4B).
However, after the Ang2 inhibitor, PECAM immunoreac-
tivity in tumor vessels had a linear pattern at endothelial
cell junctions (Figure 4C), which resembled the distribu-
tion of VE-cadherin (Figure 3C) and JAM-A (Figure 3G).
When the Ang2 inhibitor was combined with the Ang1
inhibitor, the pattern of PECAM was in the form of dots
with no apparent association with junctions (Figure 4D),
as was found in control tumors (Figure 4A).
The association of PECAM with intercellular junctions
was quantified using an algorithm, based on the multi-
scale curvelet transformat and adapted for edge detec-
tion (see Methods). The algorithm estimated the amount
of linear staining (mm of staining/mm vessel length) at
endothelial cell borders. In tumors treated with hFc (Fig-
Figure 3. Distribution of VE-cadherin and
JAM-A after inhibition of Ang1 and/or Ang2.
Fluorescence microscopic images of Colo205 tu-
mors stained for the endothelial adherens junc-
tion protein VE-cadherin or the tight junction
protein JAM-A after treatment for 26 days. VE-
cadherin immunoreactivity was weak in control
tumors (A, hFc) and after inhibition of Ang1 (B,
mL4-3) but was strong and linear at endothelial
cell borders after inhibition of Ang2 (C, L1-7(N)).
The linear pattern was not present after inhibition
of Ang1 and Ang2 (D). Immunoreactivity for the
endothelial tight junction protein JAM-A was faint
after hFc (E), Ang1 inhibition (F), or inhibition of
Ang1 and Ang2 (H), but was strong after inhibition
of Ang2 (G). Scale bar  8 m.
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ure 4E) or with the Ang1 inhibitor (Figure 4F), the identi-
fied regions of contiguous PECAM staining were small
and limited. In contrast, the algorithm identified larger
regions of PECAM staining after treatment with the Ang2
inhibitor (Figure 4G). As was evident visually, only small
regions of contiguous PECAM staining were present
when the Ang2 inhibitor was combined with the Ang1
inhibitor (Figure 4H). Linear regions of staining were sig-
nificantly larger after inhibition of Ang2 (Figure 4I). This
expansion of linear staining was not present when the two
inhibitors were combined (Figure 4I).
Differences in Pericyte Distribution after
Inhibition of Ang1 and/or Ang2
Pericytes identified by PDGFR- immunoreactivity
were abundant in tumors treated with hFc for 26 days,
but were loosely associated with tumor vessels (Figure
5A). Pericytes in tumors treated with the Ang1 inhibitor
had a similar abundance and distribution (Figure 5B).
However, after inhibition of Ang2, pericytes were more
closely associated with tumor vessels (Figure 5C).
When the Ang1 inhibitor was combined with the Ang2
inhibitor, pericytes were less closely associated with
tumor vessels (Figure 5D).
Closer examination revealed that few PDGFR-–posi-
tive pericytes were located immediately next to the ves-
sels of control tumors (Figure 5E). Pericytes were similarly
sparse near the endothelium after the Ang1 inhibitor (Fig-
ure 5F), but not after the Ang2 inhibitor, where close
associations between pericytes and endothelial cells
were numerous (Figure 5G). Blood vessels of tumors
treated with both inhibitors resembled those of tumors
treated with hFc or the Ang1 inhibitor alone (Figure 5H).
Similar staining patterns were also observed with an-
other pericyte marker, -smooth muscle actin (data not
shown).
Measurements of PDGFR-–positive pericytes tightly
associated with tumor vessels (within 10 m of the endo-
thelium) were consistent with visual impressions (Figure
5I). The amount of pericytes associated with the tumor
vessels was 114% greater after Ang2 inhibition than
those for control tumors treated with hFc (Figure 5I).
Values for the combination of inhibitors were significantly
lower than those for the Ang2 inhibitor alone and resem-
bled Ang1 inhibitor alone (Figure 5I).
Surface views of tumor vessels examined by scanning
electron microscopy revealed few pericytes in contact
with the endothelium in control tumors (Figure 5J). By
comparison, pericytes were close to the endothelium of
tumor vessels after treatment with the Ang2 inhibitor for 7
days (Figure 5K).
Discussion
These studies sought to elucidate the actions of Ang1
and Ang2 on Colo205 tumor blood vessels, with a focus
on vascular abnormalities and tumor vascularity. The ex-
periments revealed that treatment of Colo205 tumors with
the Ang2 inhibitor, L1-7(N), resulted in tumor blood ves-
sels that had more normal features, as reflected by more
uniform caliber, redistribution of VE-cadherin, JAM-A,
and PECAM to endothelial cell junctions, less sprouting,
Figure 4. Distribution of PECAM after inhibition
of Ang1 and/or Ang2. Confocal microscopic im-
ages showing the distribution of PECAM immu-
noreactivity in blood vessels of Colo205 tumors
treated for 26 days. PECAM staining was strong
in all groups (AD), but was patchy in control
tumors (A, hFc), after inhibition of Ang1 (B,
mL4-3), or after inhibition of Ang1 and Ang2
(D). By comparison, PECAM staining was
largely localized to endothelial cell junctions
after inhibition of Ang2 (C, L1-7(N)). Contiguous
linear regions of PECAM staining, identified by
the algorithm used to measure junctional nor-
malization, are marked by colored lines (E–H).
Linear PECAM staining were less in control tu-
mors (E) and after inhibition of Ang1 (F) or
inhibition of Ang1 and Ang2 (H) than after in-
hibition of Ang2 alone (G). Measurements of
contiguous linear PECAM staining revealed sig-
nificantly larger values after inhibition of Ang2
alone than after inhibition of Ang1 and Ang2 (I).
*P  0.05 compared with hFc. **P  0.05 com-
pared with Ang2 inhibitor. Scale bar  10 m.
Opposing Effects of Ang1 and Ang2 2165
AJP November 2009, Vol. 175, No. 5
and tighter association of pericytes with the endothelium.
These changes were partially or completely blocked by
concurrent inhibition of Ang1 by mL4-3. The blockade by
mL4-3 is consistent with the normalizing process being
largely mediated by unopposed actions of Ang1, and the
antagonizing action of Ang2-dominating effects of Ang1
in this system. The reduction in total tumor vascularity
after inhibition of Ang2, which were not prevented by
inhibition of Ang1, suggest that these changes result from
loss of endogenous effects of Ang2 on the tumor
vasculature.
Effect of Angiopoietin Inhibitors on Endothelial
Junctions
Vessel diameter, pericyte association, endothelial sprout-
ing, and vessel leakiness are all indicators of vascular
normalization.1,2 Here, we also use endothelial junction
markers as an indication of normalization. In endothelial
cells, junctional complexes are mainly comprised of
PECAM, adherens junctions, and tight junctions. PECAM is
an endothelial cell adhesive protein concentrated at cell
borders, which may suppress both cell activation and cell
death.40 Adherens junctions—specifically VE-cadherin in
endothelial cells—are important in contact inhibition of
cell growth, while tight junctions such as JAM-A establish
a membrane barrier to regulate permeability and cell
polarity.39,41 Ang2 inhibition led to a linear redistribution
of PECAM, VE-cadherin, and JAM-A. Collectively, these
proteins represent all classes of junctions found in endo-
thelial cells, implying a potential role for Ang2 inhibition in
suppressing endothelial cell apoptosis, preventing endo-
thelial cell growth, and reducing tumor vessel permeabil-
ity or leakiness.
Junctions go through a step-wise maturation process
to establish normal cell contacts between adjacent
cells.42 Early cell contacts begin as spot-like junctions.
Multiple cellular protrusions interlock and gradually form
Figure 5. Pericyte distribution after inhibition of
Ang1 and/or Ang2. Fluorescence microscopic
images of endothelial cells (PECAM; green) and
pericytes (PDGFR-; red) of blood vessels in
Colo205 tumors treated for 26 days. Pericytes
were loosely associated with blood vessels in
control tumors (A, hFc), after inhibition of Ang1
(B, mL4-3), or after inhibition of Ang1 and Ang2
(D) but were more closely associated with en-
dothelial cells after inhibition of Ang2 (C, L1-
7(N)). Pericytes in contact with tumor vessels
were sparse and had faint PDGFR- immunore-
activity after hFc (E), after inhibition of Ang1 (F),
or after inhibition of Ang1 and Ang2 (H) but
were abundant and had strong PDGFR- immu-
noreactivity after inhibition of Ang2 (G). Mea-
surements confirmed the greater abundance of
PDGFR--positive pericytes within 10 m of tu-
mor vessels after inhibition of Ang2 than in the
other groups (I). *P  0.05 compared with the
other groups. Scanning electron microscopic
images of the external surface of tumor vessels
showing no pericytes in contact with the endo-
thelium of a control tumor (J), in comparison with
a pericyte closely associated with the endothelium
after inhibition of Ang2 (K). Scale bar: 65 m in
A–D, 10 m in E–H, and 5 m in J–K.
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cell junctions with a zipper-like appearance. Junctions
along the entire cell border form a continuous connection
of adjacent cells, which creates the endothelial barrier.42
Blood vessels in control Colo205 tumors stained for VE-
cadherin or PECAM immunoreactivity had spot-like or
diffuse junctional staining. Ang2 inhibition changed this
irregular staining into continuous, linear staining along
the border of endothelial cells. This finding is consistent
with Ang2 activity in Colo205 tumors altering the forma-
tion, maturation, or maintenance of endothelial cell junc-
tions. Inhibition of Ang1 and Ang2 together prevented
this effect of Ang2 inhibition. Thus, unopposed activity of
Ang1—when the action of Ang2 is blocked—promotes
junctional maturation or normalization.
Importance of Tumor Vessel Normalization
Tumor blood vessels have multiple abnormalities. They
are dynamic—naturally undergoing sprouting, prolifera-
tion, remodeling, or regression. The vessels are also
leaky, irregularly shaped, tortuous, and have fewer,
loosely associated pericytes. In this study, vessel diam-
eter, pericyte association, endothelial sprouting, and en-
dothelial cell junctions were all examined as measures of
vessel normalization in Colo205 tumors. After Ang2 inhi-
bition, the tumor vessels had a more uniform caliber,
there were more pericytes associated with the tumor
vessels, there were fewer endothelial sprouts, and the
endothelial junctions were more linear. Together these
phenotypes indicate that Ang2 inhibition leads to tumor
vessel normalization. Combining Ang2 inhibition with
Ang1 inhibition prevented the effects of Ang2 inhibition
alone, indicating that unopposed Ang1 signaling is re-
sponsible for the tumor vessel normalization. These find-
ings are consistent with a previous study by Winkler et
al43 showing increased Ang1 expression associated with
tumor vessel normalization after VEGF blockade. Further
investigation is needed to determine whether unopposed
Ang1 influences vessel diameter, pericyte association,
endothelial sprouting, and endothelial junction maturation
directly or if some of these changes are consequences of
vessel normalization. However, there appears to be a role
for PDGF signaling in pericyte recruitment but not junc-
tional normalization after Ang2 inhibition. Blocking Ang2
together with PDGFR- prevents pericyte recruitment,
but the distribution of endothelial junctions is unchanged
(H. Hashizume, B. Falcon, and D. McDonald, unpub-
lished observations).
While numerous studies indicate that Ang2 acts as an
antagonist of Ang1 signaling, most of these studies have
been limited to in vitro analysis or transgenic ani-
mals.7,8,15,16 Here, we show in an in vivo tumor model that
Ang1 and Ang2 have opposing effects on tumor vessel
normalization by using Ang1 and Ang2 specific inhibi-
tors. Although these studies focused on the normalization
of vascular morphology following inhibition of angiopoi-
etins, previous studies have shown a close association
between morphological and functional changes of tumor
vessel normalization.1,17
Effects of Ang1 and Ang2 Inhibition on Tumor
Vascularity
Tumor vessels are dynamic. Growth, remodeling, and
regression are common features of tumor blood vessels.2
Inhibition of Ang2 by L1-7(N) changed this property by
normalizing the vessel wall, which decreased endothelial
sprouting and tumor vascularity. Tumor vessel normaliza-
tion did not occur when Ang2 was inhibited in the pres-
ence of the Ang1 inhibitor. However, the inhibitor combi-
nation resulted in a greater reduction in tumor vascularity
than after either inhibitor alone. This augmented loss of
tumor vessels was likely to be Ang1-independent, be-
cause it occurred in the presence of Ang1 blockade. The
reduction in tumor vascularity also may be independent
of changes in VEGF expression, as the amount of VEGF
immunoreactivity did not change with any of the treat-
ment groups (B. Falcon and D. McDonald, unpublished
data).
Tumor vessel area density and total tumor vascularity
(total area) are indicators of the dynamic state of angio-
genesis and vascular regression. Ang2 inhibition alone
did not reduce the area density of PECAM immunoreac-
tivity in tumors, but did decrease the total amount of
PECAM immunoreactivity in tumors through the decrease
in tumor size. By comparison, inhibition of Ang1 and
Ang2 together significantly reduced both tumor vessel
area density and total area. Thus, there was a greater
reduction in tumor vessels after the combination treat-
ment than after the Ang2 inhibitor alone. This greater
antivascular effect of the combination of inhibitors is likely
due to the regression of a population of tumor vessels, in
addition to the reduction in endothelial sprouting and
vessel growth found after Ang2 inhibition alone. Although
a number of factors can cause vascular regression, pre-
vention of vessel normalization by inhibition of Ang1
along with Ang2 would be expected to make tumor ves-
sels more susceptible to regression. Treatment with the
Ang2 inhibitor significantly decreased the growth rate of
Colo205 tumors. Addition of the Ang1 inhibitor to Ang2
blockade did not prevent the reduction in rate of tumor
growth, nor did it amplify it to a statistically significant
extent. However, the combination of Ang1 and Ang2
inhibitors clearly had effects on tumors different from
either inhibitor alone, as revealed by lack of tumor vessel
normalization accompanied by a greater reduction in
tumor vascularity when the inhibitors were given together.
Inhibition of Ang2 alone reduced tumor vessel growth by
stabilizing the vessel wall. The addition of the Ang1 in-
hibitor blocked the normalization and promoted vascular
regression without increasing sprouting angiogenesis.
Ang2 as a Partial Agonist
Our data imply that Ang2 prevents Ang1-dependent tu-
mor vessel normalization while influencing total tumor
vascularity independent of Ang1 signaling in Colo205
tumors. While Ang2 is described as a naturally occurring
antagonist of Ang1 signaling,7 in vitro studies have shown
that Ang2 can activate the Tie2 receptor in a concentra-
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tion or time-dependent manner.15,16 While the mecha-
nism of Ang2 acting as both an antagonist and an agonist
of the Tie2 receptor has not been elucidated, one expla-
nation is that Ang2 acts as a partial agonist.15 Ang1 and
Ang2 have similar binding sites44 and affinities for Tie2
receptors.7 Activation of Tie2 receptors by Ang2 is
weaker than by Ang1, consistent with Ang2 acting as a
partial agonist15 and Ang1 acting as a full agonist.
Differences in Ang1 and Ang2 expression in Colo205
tumors may play a role in our observed effects. Expres-
sion of Ang2, both human and mouse, was greater than
Ang1 in untreated Colo205 tumors. These results are
consistent with in situ hybridization data that show abun-
dant Ang2 expression31 but weak and diffuse Ang1 ex-
pression (S. Scully, A. Coxon, and J. Oliner; unpublished
data). Attempts were made to measure the phosphoryla-
tion state of Tie2 receptors and the downstream signaling
pathways. However, with the methods used, the baseline
phosphorylation state of Tie2 receptors, Akt, and Erk
were too low and variable to draw meaningful conclu-
sions. The amount and distribution of VEGF, as deter-
mined by immunohistochemistry, were not changed by
any of the treatments. Although this suggests that VEGF
is not a major factor in tumor vessel normalization or
decreased tumor vascularity after Ang2 inhibition, VEGF
involvement cannot be excluded because VEGF-depen-
dent actions of angiopoietins are likely to be governed by
free VEGF, which is not readily assessed by immunohis-
tochemistry or mRNA measurements.
Based on our results, we propose the following mech-
anism of Ang1 and Ang2 effects on Colo205 tumors. In
control tumors, Ang2 is expressed at much higher levels
than Ang1.31 This difference may prevent Tie2 receptor
activation by Ang1, but allow weak activation by Ang2 to
reduce vascular stability and promote angiogenesis. In-
hibition of Ang1 by mL4-3 does not affect Ang2 binding
or the subsequent weak activation of the Tie2 receptor.
Ang2 inhibition by L1-7(N) prevents Ang2 binding to Tie2
receptors. This allows binding of Ang1 to Tie2 receptors
and induction of tumor vessel normalization (stabiliza-
tion). Blocking Ang2 also prevents the partial agonist
effects of Ang2 and reduces angiogenesis and overall
tumor vascularity. Inhibition of both Ang1 and Ang2 pre-
vents Ang1-mediated vessel normalization, but the re-
duction on tumor vascularity is still observed (Figure 6).
Although this model offers a molecular basis for vessel
normalization, it is unclear how the differences in Tie2
agonism explain the alterations in tumor vascularity. Spe-
cifically, absence of vessel normalization is seen under
the three experimental conditions in which Tie2 agonism
is predicted to be the lowest (Figure 6, A, B, and D),
suggesting that Tie2 activation is linked to vessel normal-
ization. However, it is more difficult to attribute the
changes in vascularity to Tie2 activation, as the two con-
ditions in which the fewest vessels are seen (Figure 6, C
and D) are also the two conditions that are predicted to
have the greatest differences in Tie2 agonism (strong
agonism in Figure 6C and weak/absent agonism in Figure
6D). Additional experimental studies are needed to rec-
oncile this apparent disparity.
Therapeutic Implications for Ang1 and Ang2
Inhibition
Tumor growth is dependent on both vessel number and
tumor vessel function (normalization).1,2,18 Vascular nor-
malization may be a consequence of many anti-angio-
genic therapies.1,17,18 In some cases, the number of
remaining, normalized tumor vessels is enough to main-
Figure 6. Proposed mechanism of effects of in-
hibition of Ang1 and/or Ang2 on tumor blood
vessels. A: In untreated tumors, the actions of
Ang2 dominate. Ang1 acts as an agonist, but
Ang2 acts as a partial agonist that limits Ang1-
induced activation of Tie2 receptors and leads to
tumor vessel destabilization, endothelial sprout-
ing, and angiogenesis. B: Inhibition of Ang1-
induced activation of Tie2 does not change the
phenotype of tumor vessels, because Ang2 ac-
tions dominate. C: Inhibition of Ang2 leads to
the unopposed action of Ang1, which promotes
tumor vessel normalization, less sprouting, and
reduced angiogenesis. D: Inhibition of both
Ang1 and Ang2 favors tumor vessel abnormali-
ties, because of the absence of the stabilizing
action of Ang1, but also reduces sprouting, be-
cause of the absence of the angiogenesis pro-
moting action of Ang2.
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tain tumor growth.18 Current cancer therapeutics use
these normalized tumor vessels to deliver chemothera-
peutics or other cancer-cell targeting drugs more effi-
ciently.1,45,46 An alternative therapeutic objective would
be to prevent tumor vessel normalization to keep tumor
vessels unstable and subject to regression.
Here, we show that tumor vessel normalization in
Colo205 tumors is dependent on unopposed Ang1 sig-
naling. Ang2 expression or inhibition of Ang1 with mL4-3
prevents tumor vessel normalization. Thus, dual inhibition
of Ang1 and Ang2 may provide improved therapeutic
benefit over selective Ang2 inhibition by reducing tumor
vessels while preventing the undesired consequences of
tumor vessel normalization.
Growth and maintenance of blood vessels in tumors
are dependent on multiple growth factors. Thus angio-
genesis inhibitors that block multiple targets are being
developed for treatment of solid tumors. A better under-
standing of the interplay among growth factors is needed
to advance growth factor-targeted cancer therapeutics.
Here, we show that in the absence of Ang2, Ang1 drives
tumor vessels into a more normal phenotype. In evidence
of this change, inhibition of Ang2 resulted in normaliza-
tion of endothelial cell junctions, pericyte coverage, and
overall architecture of blood vessels in Colo205 tumors.
This normalization was prevented by blocking Ang1. In-
hibition of Ang2 also reduced tumor vascularity, and this
action was augmented by simultaneous inhibition of
Ang1.
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